Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | SDHB | P21912 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049884 | 0.84 | GRM5 (0.38) | TGFBR1CDK8PDE4DNPC1RAB9A | |
| SCHEMBL1041122 | 0.73 | RAB9A (0.40) | NPC1RAB9A | |
| SCHEMBL1036911 | 0.71 | HRH4 (0.34) | — | |
| SCHEMBL1041001 | 0.70 | MAPK9 (0.46) | RAB9A | |
| SCHEMBL5558179 | 0.68 | CDK8 (0.56) | TGFBR1CA12CA1CA2CA9 | |
| SCHEMBL1950804 | 0.68 | CDK8 (0.56) | CA12CA1CA2CA9CDK8 | |
| SCHEMBL67941 | 0.68 | CA12 (0.68) | CA12CA1CA2CA9CDK8 | |
| SCHEMBL31351037 | 0.67 | IRAK4 (0.47) | NPC1RAB9ADGAT2 | |
| SCHEMBL8443288 | 0.67 | CNR1 (0.56) | CA12CA1CA2CA9CDK8 | |
| SCHEMBL1950004 | 0.67 | CDK8 (0.54) | CA12CA1CA2CA9CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853596-B1 | NOVEL, LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-1720546-B1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-7423036-B2 | Long-acting betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423036-B2 | Long-acting betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7405232-B2 | Long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-29 | — | — | US | disclosed |
| US-7405232-B2 | Long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-29 | — | — | US | disclosed |
| US-7405232-B2 | Long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-29 | — | — | US | disclosed |
| WO-2008017637-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017638-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| US-20060189607-A1 | Long-acting betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| US-20050197374-A1 | New long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197374-A1 | New long acting beta-2 agonists and their use as medicaments | ADRB2, ADRA2A, ADRA2C | TGFBR1 110/4885CA12 3699/4885CA1 4749/4885 |
| US-20060189607-A1 | Long-acting betamimetics for the treatment of respiratory complaints | ADRA1A, ADRA1D, ADRA2A | TGFBR1 344/4885CA12 2844/4885CA1 2543/4885 |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | NDUFA1, NDUFA6, NDUFA3 | TGFBR1 2494/4885CA12 794/4885CA1 2102/4885 |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | ADRB1, ADRA1A, ADRB2 | TGFBR1 202/4885CA12 3432/4885CA1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.